P/E Ratio

The current P/E ratio of 18.5x means investors are paying $18.50 for every $1 of Biogen’s earnings over the past twelve months — a common measure of how expensive or cheap a stock is relative to its profits.

Compared to healthcare sector peers, Biogen’s P/E sits well below the sector median of 24.6x, placing it in the 26th percentile — meaning only about a quarter of peers are cheaper on this basis. No year-over-year or quarter-over-quarter changes are available for this metric, and the trend over the last eight quarters is also not reported, so there is no directional signal from recent movements. The combination of a below-median P/E with no trend data suggests Biogen may be priced at a discount to its sector, but without evidence of improvement or deterioration, the risk-reward balance is unclear. This metric supports the overall NEUTRAL verdict because the moderate valuation relative to peers does not point decisively to either an undervalued opportunity or an overvalued risk, especially given the lack of trend history.

Frequently Asked Questions

Closest Sector Peers